Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Advaxis seeks FDA approval to begin first-in-human trial of ADXS-HER2
The trial is scheduled to start in the first quarter of 2015. It is designed to evaluate the safety and tolerability of ADXS-HER2 in patients diagnosed with metastatic
The trial is scheduled to start in the first quarter of 2015. It is designed to evaluate the safety and tolerability of ADXS-HER2 in patients diagnosed with metastatic
The two parties have also entered into an exclusive license agreement that allows BMS to develop, manufacture and commercialize Calibr’s preclinical compounds resulting from the collaboration. Bristol-Myers Squibb
The aerosol foam formulation of the fixed combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%, has been developed to improve treatment for patients with plaque psoriasis. The NDA is
The injection is designed to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system (CNS). Previously, gadavist was approved for
The company also secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for this product, which is indicated to
The transaction also includes intellectual property and a technology platform related to a second, undisclosed vaccine program. CMV is a herpes virus and one out of every five
AQX-1125 is a small molecule activator of SHIP1, which is a regulating component of the PI3K cellular signaling pathway. The randomized, double-blind, multicenter, placebo-controlled Phase II KINSHIP trial
The randomized, double-blind, placebo-controlled Phase Ib trial is currently underway at Clinical Pharmacology of Miami. It is designed to further evaluate the safety, tolerability and pharmacokinetics of multiple-ascending
Remodulin Injection is indicated to treat patients with pulmonary arterial hypertension (PAH) via a pre-filled semi-disposable pump system. The company intends to launch the new subcutaneous Remodulin delivery
As part of the deal, Knight will pay around $1.75m cash as well as offer additional funding to further develop new pharmaceutical products. The deal will see establishment